MX2019005937A - Metodos para identificar pacientes de esquizofrenia en riesgo de recaer. - Google Patents

Metodos para identificar pacientes de esquizofrenia en riesgo de recaer.

Info

Publication number
MX2019005937A
MX2019005937A MX2019005937A MX2019005937A MX2019005937A MX 2019005937 A MX2019005937 A MX 2019005937A MX 2019005937 A MX2019005937 A MX 2019005937A MX 2019005937 A MX2019005937 A MX 2019005937A MX 2019005937 A MX2019005937 A MX 2019005937A
Authority
MX
Mexico
Prior art keywords
relapse
methods
risk
schizophrenia patients
identifying
Prior art date
Application number
MX2019005937A
Other languages
English (en)
Spanish (es)
Inventor
Wang Dai
Baker Susan
Gopal Srihari
Narayan Vaibhav
Savitz Adam
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2019005937A publication Critical patent/MX2019005937A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
    • A61B5/167—Personality evaluation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
    • A61B5/165—Evaluating the state of mind, e.g. depression, anxiety
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Educational Technology (AREA)
  • Social Psychology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
MX2019005937A 2016-11-22 2017-11-21 Metodos para identificar pacientes de esquizofrenia en riesgo de recaer. MX2019005937A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662425257P 2016-11-22 2016-11-22
US201662434587P 2016-12-15 2016-12-15
PCT/US2017/062682 WO2018098109A2 (fr) 2016-11-22 2017-11-21 Méthodes d'identification de patients atteints de schizophrénie à risque de rechute

Publications (1)

Publication Number Publication Date
MX2019005937A true MX2019005937A (es) 2019-11-18

Family

ID=62144543

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005937A MX2019005937A (es) 2016-11-22 2017-11-21 Metodos para identificar pacientes de esquizofrenia en riesgo de recaer.

Country Status (11)

Country Link
US (2) US11723569B2 (fr)
EP (1) EP3545315A4 (fr)
JP (2) JP2020511174A (fr)
KR (1) KR102655245B1 (fr)
AU (1) AU2017363596A1 (fr)
BR (1) BR112019010324A2 (fr)
CA (1) CA3044545A1 (fr)
MA (1) MA46910A (fr)
MX (1) MX2019005937A (fr)
TW (1) TW201831213A (fr)
WO (1) WO2018098109A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022505676A (ja) * 2018-10-23 2022-01-14 ブラックソーン セラピューティクス インコーポレイテッド 患者のスクリーニング、診断、及び層別化のためのシステム及び方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006505489A (ja) * 2002-02-08 2006-02-16 アボット・ラボラトリーズ 精神分裂病の治療のための併用療法
US20070172831A1 (en) 2003-06-19 2007-07-26 Altar C A Schizophrenia gene signatures and methods of using the same
GB0502979D0 (en) 2005-02-14 2005-03-16 Univ Cambridge Tech Biomarkers and uses thereof
GB0701626D0 (en) 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
GB0724735D0 (en) 2007-12-19 2008-01-30 Psynova Neurotech Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
EP2868753A1 (fr) 2008-09-25 2015-05-06 SureGene LLC Marqueurs génétiques pour optimiser le traitement de la schizophrénie
WO2011041725A2 (fr) 2009-10-01 2011-04-07 The Regents Of The University Of Colorado, A Body Corporate Biomarqueurs de réponse à un traitement de la schizophrénie
JP5840124B2 (ja) 2010-05-14 2016-01-06 公益財団法人東京都医学総合研究所 統合失調症の検出方法
NZ709258A (en) 2012-12-11 2020-05-29 Ami Klin Systems and methods for detecting blink inhibition as a marker of engagement and perceived stimulus salience
NL2010214C2 (en) 2013-01-31 2014-08-04 Brainlabs B V Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness.
GB201404189D0 (en) 2014-03-10 2014-04-23 Cambridge Entpr Ltd Novel biomarkers
PL408860A1 (pl) 2014-07-15 2016-01-18 Moneo Pharma Group Spółka Z Ograniczoną Odpowiedzialnością Telemedyczny sposób i system monitorowania pacjenta

Also Published As

Publication number Publication date
CA3044545A1 (fr) 2018-05-31
KR20190086524A (ko) 2019-07-22
KR102655245B1 (ko) 2024-04-05
US20230301573A1 (en) 2023-09-28
AU2017363596A1 (en) 2019-06-06
MA46910A (fr) 2019-10-02
EP3545315A2 (fr) 2019-10-02
US11723569B2 (en) 2023-08-15
EP3545315A4 (fr) 2020-11-25
JP2023138945A (ja) 2023-10-03
WO2018098109A2 (fr) 2018-05-31
WO2018098109A3 (fr) 2018-06-28
TW201831213A (zh) 2018-09-01
BR112019010324A2 (pt) 2019-08-27
US20180140242A1 (en) 2018-05-24
JP2020511174A (ja) 2020-04-16

Similar Documents

Publication Publication Date Title
SA517390218B1 (ar) جهاز وطرق لتحديد النسيج التالف باستخدام قياسات الرطوبة تحت الجلد
MY194686A (en) Detection of chromosome interactions
PH12017500293A1 (en) Boronic acid derivatives
BR112015029318A2 (pt) marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável
MX2016009060A (es) Metodos y sistemas para determinar el riesgo de falla cardiaca.
NZ631031A (en) Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
MX2017004043A (es) Derivados de acido boronico.
MX2017004046A (es) Derivados de acido boronico.
BR112015030526A2 (pt) detecção de aorta automatizada em um volume de tca
MX2015013436A (es) Metodo de determinacion del sexo de un embrion en un huevo.
MX2019003998A (es) Metodo de evaluacion de vehiculo, metodo de correcion de ruta de desplazamiento, dispositivo de evaluacion de vehiculo, y dispositivo de correccion de ruta de desplazamiento.
MX358474B (es) Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson.
IL249237A0 (en) Ornithodorus Mobate complement inhibitor for use in the treatment of complement-induced diseases in patients with the c5 polymorphism
MX2021009528A (es) Prueba de diagnostico basada en fragmento de rgma.
GB2542997A (en) Device and method for monitoring of annulus volume in a pipe
MX358693B (es) Indicador de migracion doble.
MX2019005937A (es) Metodos para identificar pacientes de esquizofrenia en riesgo de recaer.
MX2016011746A (es) Casete de fluido con seguro de alineacion que tiene una tolerancia a la inclinacion mejorada, asi como un aparato de tratamiento de la sangre.
FR3027675B1 (fr) Procede de caracterisation de la concentration en oxygene interstitiel dans un lingot semi-conducteur
MX2014011045A (es) Metodo para seleccionar o identificar un sujeto para la terapia antagonista vib.
MX2017007324A (es) Sistema y metodo de eliminacion de los contaminantes de los recortes de perforacion.
NZ703905A (en) Method of treating multiple sclerosis by using narrow band uvb
LV14878A (lv) Vairogdziedzera papillāra vēža riska noteikšanas paņēmiens pacientiem ar vairogdziedzera mezgliem
UA96099U (uk) Спосіб прогнозування зрощення перелому
UA96067U (uk) Спосіб прогнозування зрощення перелому